Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting

Role of Immunotherapy for Renal Cell Cancer in 2011

“…Various studies showed that transplantation induced a long-term disease-free interval in a small fraction of patients. 38,39 The development of a graft-versus-tumor effect is thought to be the reason for response among the patients who showed clinical benefit. 40–42 Various vaccine-based approaches are being explored in RCC in the adjuvant and meta-static settings.…”

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma

“…In their recent report, Bregni and co-workers observed a five-year survival rate of 20% for 25 patients with metastatic RCC treated by RIC and allogeneic HCT from HLA-compatible sibling donors. Of interest, three long-term survivors had stable metastatic disease and had received posttransplant vascular endothelial growth factor (VEGF)-receptor targeted tyrosine-kinase inhibitors including sunitinib or sorafenib 3. The authors further speculate on the potential for clinical benefit by combining allogeneic HCT with novel targeted therapies for metastatic RCC.…”

“…Retrospective analyses of RCC patients treated by RIC and allogeneic HCT have suggested that RCC patients from favorable or intermediate risk groups defined by MSKCC prognostic criteria and with clear cell tumors have achieved better outcomes 2, 3. However, RCC patients with these clinical features are most likely to receive initial treatment with VEGF-targeted therapies including sunitinib or bevacizumab plus IFN-α based on results of phase III clinical studies 4, 5.…”

“…The onset of RCC regression following allogeneic HCT is typically delayed by several months and early posttransplant disease progression has been strongly associated with treatment failure and short survival 1–3. Recognizing that good performance patients with clear cell RCC seeking experimental therapies will likely have failed one or more prior VEGF-targeted treatments, combining allogeneic HCT with an mTOR inhibitor represents a compelling strategy that may delay posttransplant tumor progression favoring the development of GVT activity.…”

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)

“…Survival of patients at favorable/intermediate‐risk according to the MSKCC score that underwent allografting was better in comparison to the survival predicted by historical controls. They concluded that 20% of cytokine‐refractory RCC patients are alive long‐term after allografting, and that transplantation is able to induce long‐term disease control in a fraction of relapsed RCC patients4.…”